Does Chromium Fasting Glucose Randomized Trial work?

Updated July 2026

Quick Answer

Chromium Fasting Glucose Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: 1 1 2 Table 1 Aspect Details References Metabolic syndrome is a cluster of conditions that increase the risk of heart disease, stroke, and diabetes.

Key Takeaways

  • 011 1 2 Table 1 Aspect Details References Metabolic syndrome is a cluster of conditions that increase the risk of heart disease, stroke, and diabetes. [Babakr Abdullatif Taha (2026)]
  • 021 [] Common risk factors include obesity (BMI ≥ 25 kg/m), increased waist circumference (>102 cm for men, >88 cm for women), hypertension, smoking, hyperlipidemia, age > 40 years, and a history of gestational diabetes. [Babakr Abdullatif Taha (2026)]
  • 035 [] Metabolic syndrome increases the risk of cardiovascular diseases, kidney disease, eye problems, neuropathy, and diabetes-related complications such as foot ulcers and amputations. [Babakr Abdullatif Taha (2026)]
  • 04It includes central obesity, insulin resistance, hypertension, and dyslipidemia. [Babakr Abdullatif Taha (2026)]
The current Migaku evidence database contains 2 reusable source documents for Chromium Fasting Glucose Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove. - 1 1 2 Table 1 Aspect Details References Metabolic syndrome is a cluster of conditions that increase the risk of heart disease, stroke, and diabetes. [Babakr Abdullatif Taha (2026); evidence level 1] - 1 [] Common risk factors include obesity (BMI ≥ 25 kg/m), increased waist circumference (>102 cm for men, >88 cm for women), hypertension, smoking, hyperlipidemia, age > 40 years, and a history of gestational diabetes. [Babakr Abdullatif Taha (2026); evidence level 1] - 5 [] Metabolic syndrome increases the risk of cardiovascular diseases, kidney disease, eye problems, neuropathy, and diabetes-related complications such as foot ulcers and amputations. [Babakr Abdullatif Taha (2026); evidence level 1] - It includes central obesity, insulin resistance, hypertension, and dyslipidemia. [Babakr Abdullatif Taha (2026); evidence level 1] - Reduced insulin receptor sensitivity leads to a significant decline in insulin efficacy during glucose metabolism, further promoting hyperinsulinemia. [Ye Jiahui (2026); evidence level 1] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes
  2. Effectiveness of mineral supplements (magnesium, chromium, zinc, selenium, chromium picolinate) in reducing insulin resistance in polycystic ovary syndrome: a meta-analysis of randomized controlled trials